Search

Your search keyword '"Campbell, Ross T."' showing total 198 results
Start Over Author "Campbell, Ross T."
198 results on '"Campbell, Ross T."'

2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

Author

Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

4. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design

Author

Carberry, Jaclyn, primary, Petrie, Mark C., additional, Lee, Matthew M.Y., additional, Brooksbank, Katriona, additional, Campbell, Ross T., additional, Good, Richard, additional, Jhund, Pardeep S., additional, Kellman, Peter, additional, Lang, Ninian N., additional, Mangion, Kenneth, additional, Mark, Patrick B., additional, McConnachie, Alex, additional, McMurray, John J.V., additional, Meyer, Barbara, additional, Orchard, Vanessa, additional, Shaukat, Aadil, additional, Watkins, Stuart, additional, Welsh, Paul, additional, Sattar, Naveed, additional, Berry, Colin, additional, and Docherty, Kieran F., additional

Published
2024
Full Text
View/download PDF

5. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

7. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction

Author

McDowell, Kirsty, primary, Kondo, Toru, additional, Talebi, Atefeh, additional, Teh, Ken, additional, Bachus, Erasmus, additional, de Boer, Rudolf A., additional, Campbell, Ross T., additional, Claggett, Brian, additional, Desai, Ashkay S., additional, Docherty, Kieran F., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S. P., additional, Martinez, Felipe, additional, Simpson, Joanne, additional, Vaduganathan, Muthiah, additional, Jhund, Pardeep S., additional, Solomon, Scott D., additional, and McMurray, John J. V., additional

Published
2024
Full Text
View/download PDF

9. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Author

Osmanska, Joanna, primary, Brooksbank, Katriona, additional, Docherty, Kieran F, additional, Robertson, Stacy, additional, Wetherall, Kirsty, additional, McConnachie, Alex, additional, Hu, Jerry, additional, Gardner, Roy S, additional, Clark, Andrew L, additional, Squire, Iain B, additional, Kalra, Paul R, additional, Jhund, Pardeep S, additional, Muntendam, Pieter, additional, McMurray, John J V, additional, Petrie, Mark C, additional, and Campbell, Ross T, additional

Published
2023
Full Text
View/download PDF

11. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Author

Preiss, David, Campbell, Ross T, Murray, Heather M, Ford, Ian, Packard, Chris J, Sattar, Naveed, Rahimi, Kazem, Colhoun, Helen M, Waters, David D, LaRosa, John C, Amarenco, Pierre, Pedersen, Terje R, Tikkanen, Matti J, Koren, Michael J, Poulter, Neil R, Sever, Peter S, Ridker, Paul M, MacFadyen, Jean G, Solomon, Scott D, Davis, Barry R, Simpson, Lara M, Nakamura, Haruo, Mizuno, Kyoichi, Marfisi, Rosa M, Marchioli, Roberto, Tognoni, Gianni, Athyros, Vasilios G, Ray, Kausik K, Gotto, Antonio M, Clearfield, Michael B, Downs, John R, and McMurray, John J

Subjects
Clinical Trials and Supportive Activities, Cardiovascular, Clinical Research, Prevention, Heart Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Female, Heart Failure, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Myocardial Infarction, Randomized Controlled Trials as Topic, Risk Factors, Secondary Prevention, Treatment Outcome, Statin, Heart failure, Randomized trial, Meta-analysis, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsThe effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish whether statins reduce major HF events.Methods and resultsWe searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized controlled endpoint statin trials from 1994 to 2014. Collaborating trialists provided unpublished data from adverse event reports. We included primary- and secondary-prevention statin trials with >1000 participants followed for >1 year. Outcomes consisted of first non-fatal HF hospitalization, HF death and a composite of first non-fatal HF hospitalization or HF death. HF events occurring

Published
2015

13. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Author

Matsumoto, Shingo, primary, Kondo, Toru, additional, Yang, Mingming, additional, Campbell, Ross T, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Packer, Milton, additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

18. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

Author

Yeoh, Su Ern, primary, Osmanska, Joanna, additional, Petrie, Mark C, additional, Brooksbank, Katriona J M, additional, Clark, Andrew L, additional, Docherty, Kieran F, additional, Foley, Paul W X, additional, Guha, Kaushik, additional, Halliday, Crawford A, additional, Jhund, Pardeep S, additional, Kalra, Paul R, additional, McKinley, Gemma, additional, Lang, Ninian N, additional, Lee, Matthew M Y, additional, McConnachie, Alex, additional, McDermott, James J, additional, Platz, Elke, additional, Sartipy, Peter, additional, Seed, Alison, additional, Stanley, Bethany, additional, Weir, Robin A P, additional, Welsh, Paul, additional, McMurray, John J V, additional, and Campbell, Ross T, additional

Published
2023
Full Text
View/download PDF

20. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Ern Yeoh, Su, primary, Docherty, Kieran F., additional, Campbell, Ross T., additional, Jhund, Pardeep S., additional, Hammarstedt, Ann, additional, Heerspink, Hiddo J.L., additional, Jarolim, Petr, additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, Ponikowski, Piotr, additional, Solomon, Scott D., additional, Sjöstrand, Mikaela, additional, Bengtsson, Olof, additional, Greasley, Peter J., additional, Sattar, Naveed, additional, Welsh, Paul, additional, Sabatine, Marc S., additional, Morrow, David A., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

21. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Author

Osmanska, Joanna, Brooksbank, Katriona, Docherty, Kieran F, Robertson, Stacy, Wetherall, Kirsty, McConnachie, Alex, Hu, Jerry, Gardner, Roy S, Clark, Andrew L, Squire, Iain B, Kalra, Paul R, Jhund, Pardeep S, Muntendam, Pieter, McMurray, John J V, Petrie, Mark C, and Campbell, Ross T

Abstract

Graphical Abstract

Published
2024
Full Text
View/download PDF

23. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.

Author

Matsumoto, Shingo, Kondo, Toru, Yang, Mingming, Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Desai, Akshay S., Lam, Carolyn S.P., Packer, Milton, Pitt, Bertram, Rouleau, Jean L., Vaduganathan, Muthiah, Zannad, Faiez, Zile, Michael R., Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Subjects
HEART failure patients, CALCIUM antagonists, VENTRICULAR ejection fraction, TREATMENT effectiveness, HEART failure
Abstract

Aims: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. We aimed to investigate the association between CCB use and clinical outcomes in patients with HFmrEF/HFpEF; CCBs were examined overall, as well as by subtype (dihydropyridine and non‐dihydropyridine). Methods and results: We pooled individual patient data from four large HFpEF/HFmrEF trials. The association between CCB use and outcomes was assessed. Among the 16 954 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 402 (79.0%) had HFpEF (LVEF ≥50%). Altogether, 5874 patients (34.6%) received a CCB (87.6% dihydropyridines). Overall, the risks of death and HF hospitalization were not higher in patients treated with a CCB, particularly dihydropyridines. The risk of pump failure death was significantly lower (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.60–0.96), while the risk of stroke was higher (HR 1.26, 95% CI 1.06–1.50) in patients treated with a CCB compared to those not. These risks remained different in patients treated and not treated with a CCB after adjustment for other prognostic variables. Although the majority of patients were treated with dihydropyridine CCBs, the pattern of outcomes was broadly similar for both dihydropyridine and non‐dihydropyridine CCBs. Conclusion: Although this is an observational analysis of non‐randomized treatment, there was no suggestion that CCBs were associated with worse HF outcomes. Indeed, CCB use was associated with a lower incidence of pump failure death. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction

Author

Dewan, Pooja, Rørth, Rasmus, Raparelli, Valeria, Campbell, Ross T., Shen, Li, Jhund, Pardeep S., Petrie, Mark C., Anand, Inder S., Carson, Peter E., Desai, Akshay S., Granger, Christopher B., Køber, Lars, Komajda, Michel, McKelvie, Robert S., O’Meara, Eileen, Pfeffer, Marc A., Pitt, Bertram, Solomon, Scott D., Swedberg, Karl, Zile, Michael R., and McMurray, John J.V.

Published
2019
Full Text
View/download PDF

27. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort

Author

Welsh, Paul, primary, Campbell, Ross T., additional, Mooney, Leanne, additional, Kimenai, Dorien M., additional, Hayward, Caroline, additional, Campbell, Archie, additional, Porteous, David, additional, Mills, Nicholas L., additional, Lang, Ninian N., additional, Petrie, Mark C., additional, Januzzi, James L., additional, McMurray, John J.V., additional, and Sattar, Naveed, additional

Published
2022
Full Text
View/download PDF

29. Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Author

Lee, Matthew M.Y., primary, Gillis, Keith A., additional, Brooksbank, Katriona J.M., additional, Allwood-Spiers, Sarah, additional, Hall Barrientos, Pauline, additional, Wetherall, Kirsty, additional, Roditi, Giles, additional, AlHummiany, Bashair, additional, Berry, Colin, additional, Campbell, Ross T., additional, Chong, Victor, additional, Coyle, Liz, additional, Docherty, Kieran F., additional, Dreisbach, John G., additional, Kuehn, Bernd, additional, Labinjoh, Catherine, additional, Lang, Ninian N., additional, Lennie, Vera, additional, Mangion, Kenneth, additional, McConnachie, Alex, additional, Murphy, Clare L., additional, Petrie, Colin J., additional, Petrie, John R., additional, Sharma, Kanishka, additional, Sourbron, Steven, additional, Speirits, Iain A., additional, Thompson, Joyce, additional, Welsh, Paul, additional, Woodward, Rosemary, additional, Wright, Ann, additional, Radjenovic, Aleksandra, additional, McMurray, John J.V., additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, Sattar, Naveed, additional, and Mark, Patrick B., additional

Published
2022
Full Text
View/download PDF

31. Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) Study Protocol.

Author

Cameron, Alan C., Katsas, Georgios, Arnold, Markus, Docherty, Kieran, Campbell, Ross T., Murdoch, David, McClure, John D., Katan, Mira, Lip, Gregory Y.H., Abdul-Rahim, Azmil H., and Dawson, Jesse

Subjects
STROKE, TRANSIENT ischemic attack, ISCHEMIC stroke, PATIENTS' rights, STROKE units, SCIENTIFIC community, CARDIAC intensive care
Abstract

Cardiac rhythm monitoring is performed to search for atrial fibrillation (AF) after ischaemic stroke or transient ischaemic attack (TIA). Prolonged cardiac rhythm monitoring increases AF detection but is challenging to implement in many healthcare settings and is not needed for all people after ischaemic stroke/TIA. We aimed to develop and validate a model that includes clinical, electrocardiogram (ECG), blood-based, and genetic biomarkers to identify people with a low probability of AF detection after ischaemic stroke or TIA. We will recruit 675 consenting participants who are aged over 18 years, who were admitted with ischaemic stroke or TIA in the 5 days prior, who are not known to have AF, and who would be suitable for anticoagulation if AF is found. We will collect baseline demographic and clinical data, a 12-lead ECG, and a venous blood sample for blood biomarkers (including midregional pro-atrial natriuretic peptide, MRproANP) and genetic data. We will perform up to 28 days of cardiac rhythm monitoring using an R-test or patch device to search for AF in all participants. The sample size of 675 participants is based on true sensitivity of 92.5%, null hypothesis sensitivity of 80%, 80% power, and 5% significance. The primary outcome is AF detection ≥30 s duration during 28 days of cardiac rhythm monitoring. Secondary outcomes are AF detection at 1-year, recurrent cardiovascular events, and mortality and will be identified by electronic linkage and telephone follow-up. The results will guide the development of a more personalized care pathway to search for AF after ischaemic stroke or TIA. This could help to reduce cardiac rhythm monitoring for people with a low probability of AF detection and allow more intensive cardiac monitoring to be focused on people who are more likely to have AF and benefit. Participants will be consented for their data to be used in future research studies, providing a rich resource for stroke and cardiovascular research communities. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion.

Author

Lee, Matthew M.Y., Campbell, Ross T., Claggett, Brian L., Lewis, Eldrin F., Docherty, Kieran F., Lindner, Moritz, Liu, Jiankang, Solomon, Scott D., McMurray, John J.V., and Platz, Elke

Subjects
*BRAIN natriuretic factor, *HEART failure, *QUALITY of life, *VENTRICULAR ejection fraction
Abstract

Aims: The aim of this study was to examine the association between patient‐reported symptoms and the extent of pulmonary congestion in acute heart failure (AHF). Methods and results: In this prospective, observational study, patient‐reported symptoms were assessed at baseline using the Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ‐TSS) (range 0–100; 0 worst) in patients hospitalized for AHF. In a subset, patient‐reported dyspnoea at rest and on exertion was examined (range 0–10; 10 worst) at baseline. In addition, 4‐zone lung ultrasound (LUS) was performed at baseline at the time of echocardiography. B‐lines were quantified offline, blinded to clinical findings, by a core laboratory. Chest X‐ray (CXR) and physical examination findings were collected from the medical records. Among 322 patients (mean age 72, 60% men, mean left ventricular ejection fraction 39%) with AHF, the median KCCQ‐TSS score was 33 (interquartile range 18–48). Worse KCCQ‐TSS was associated with worse New York Heart Association class, dyspnoea at rest and on exertion, and peripheral oedema (p trend <0.001 for all). However, KCCQ‐TSS was not associated with the extent of pulmonary congestion, as assessed by the number of B‐lines on LUS, or findings on CXR, or physical examination (p trend >0.25 for all). Similarly, KCCQ‐TSS was not significantly associated with echocardiographic markers of left ventricular filling pressure, pulmonary pressure or with N‐terminal pro‐B‐type natriuretic peptide level. Conclusions: Among patients hospitalized for AHF, at baseline, KCCQ‐TSS was not associated with pulmonary congestion assessed by LUS, CXR, or physical examination. These findings suggest that the profound reduction in KCCQ‐TSS in patients with AHF may not be solely explained by pulmonary congestion. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Influenza vaccination: Simple, safe, and effective for patients with ischaemic heart disease and heart failure.

Author

Brennan, Alice C., Campbell, Ross T., and Lee, Matthew M.Y.

Subjects
*HEART failure, *ATHEROSCLEROTIC plaque, *CARDIAC patients, *INFLUENZA vaccines, *DRUG-eluting stents, *VENTRICULAR ejection fraction
Abstract

Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis. B This article refers to 'Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis' by D. Modin I et al i ., published in this issue on pages 1685-1692. b Annual influenza epidemics are estimated to cause between 290 000-650 000 respiratory deaths per year - however, this estimate does not include cardiovascular (CV) deaths.[1] Influenza infection is associated with increased risk of CV events, particularly among individuals at high CV risk.[2] Multiple pathophysiological mechanisms have been proposed to explain the associated increase in CV outcomes in individuals with influenza infection, such as atherosclerotic plaque rupture and an increased risk of atherothrombosis (secondary to the release of pro-inflammatory cytokines resulting in a pro-thrombotic milieu, influx of inflammatory cells, plaque destabilization, and endothelial dysfunction), increased metabolic demand due to sympathetic activation (leading to tachycardia and hypoxaemia, exacerbating supply-demand mismatch), or by direct viral effect or triggering of myocarditis.[[3]] Influenza vaccination (IV) is widely acknowledged as the most effective way to prevent seasonal influenza, reduce disease severity, and lower the incidence of complications and deaths.[1] It is, therefore, intuitive that IV might reduce the risk of CV events in at-risk patients, although until recently randomized controlled trials (RCTs) specifically addressing this hypothesis were small and varied in quality. Five of the six trials included patients with IHD, while the recently published Influenza Vaccine to Prevent Adverse Vascular Events (IVVE) trial included patients with HF.[6] The follow-up duration ranged from 10 to 36 months. [Extracted from the article]

Published
2023
Full Text
View/download PDF

34. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction

Author

Rush, Christopher J., primary, Berry, Colin, additional, Oldroyd, Keith G., additional, Rocchiccioli, J. Paul, additional, Lindsay, M. Mitchell, additional, Touyz, Rhian M., additional, Murphy, Clare L., additional, Ford, Thomas J., additional, Sidik, Novalia, additional, McEntegart, Margaret B., additional, Lang, Ninian N., additional, Jhund, Pardeep S., additional, Campbell, Ross T., additional, McMurray, John J. V., additional, and Petrie, Mark C., additional

Published
2021
Full Text
View/download PDF

35. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

Author

Docherty, Kieran F., primary, Campbell, Ross T., additional, Brooksbank, Katriona J.M., additional, Dreisbach, John G., additional, Forsyth, Paul, additional, Godeseth, Rosemary L., additional, Hopkins, Tracey, additional, Jackson, Alice M., additional, Lee, Matthew M.Y., additional, McConnachie, Alex, additional, Roditi, Giles, additional, Squire, Iain B., additional, Stanley, Bethany, additional, Welsh, Paul, additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, and McMurray, John J.V., additional

Published
2021
Full Text
View/download PDF

39. Urinary peptides in heart failure: a link to molecular pathophysiology

Author

He, Tianlin, primary, Mischak, Michaela, additional, Clark, Andrew L., additional, Campbell, Ross T., additional, Delles, Christian, additional, Díez, Javier, additional, Filippatos, Gerasimos, additional, Mebazaa, Alexandre, additional, McMurray, John J.V., additional, González, Arantxa, additional, Raad, Julia, additional, Stroggilos, Rafael, additional, Bosselmann, Helle S., additional, Campbell, Archie, additional, Kerr, Shona M., additional, Jackson, Colette E., additional, Cannon, Jane A., additional, Schou, Morten, additional, Girerd, Nicolas, additional, Rossignol, Patrick, additional, McConnachie, Alex, additional, Rossing, Kasper, additional, Schanstra, Joost P., additional, Zannad, Faiez, additional, Vlahou, Antonia, additional, Mullen, William, additional, Jankowski, Vera, additional, Mischak, Harald, additional, Zhang, Zhenyu, additional, Staessen, Jan A., additional, and Latosinska, Agnieszka, additional

Published
2021
Full Text
View/download PDF

40. Sex differences in congestive markers in patients hospitalized for acute heart failure

Author

Espersen, Caroline, primary, Campbell, Ross T., additional, Claggett, Brian, additional, Lewis, Eldrin F., additional, Groarke, John D., additional, Docherty, Kieran F., additional, Lee, Matthew M.Y., additional, Lindner, Moritz, additional, Biering‐Sørensen, Tor, additional, Solomon, Scott D., additional, McMurray, John J.V., additional, and Platz, Elke, additional

Published
2021
Full Text
View/download PDF

41. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Author

Lee, Matthew M.Y., primary, Brooksbank, Katriona J.M., additional, Wetherall, Kirsty, additional, Mangion, Kenneth, additional, Roditi, Giles, additional, Campbell, Ross T., additional, Berry, Colin, additional, Chong, Victor, additional, Coyle, Liz, additional, Docherty, Kieran F., additional, Dreisbach, John G., additional, Labinjoh, Catherine, additional, Lang, Ninian N., additional, Lennie, Vera, additional, McConnachie, Alex, additional, Murphy, Clare L., additional, Petrie, Colin J., additional, Petrie, John R., additional, Speirits, Iain A., additional, Sourbron, Steven, additional, Welsh, Paul, additional, Woodward, Rosemary, additional, Radjenovic, Aleksandra, additional, Mark, Patrick B., additional, McMurray, John J.V., additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, and Sattar, Naveed, additional

Published
2021
Full Text
View/download PDF

42. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling

Author

Docherty, Kieran F., primary, Campbell, Ross T., additional, Brooksbank, Katriona J.M., additional, Godeseth, Rosemary L., additional, Forsyth, Paul, additional, McConnachie, Alex, additional, Roditi, Giles, additional, Stanley, Bethany, additional, Welsh, Paul, additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, and McMurray, John J.V., additional

Published
2020
Full Text
View/download PDF

43. A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction

Author

Docherty, Kieran F., primary, Campbell, Ross T., additional, Brooksbank, Katriona J.M., additional, Godeseth, Rosemary L., additional, Forsyth, Paul, additional, McConnachie, Alex, additional, Roditi, Giles, additional, Stanley, Bethany, additional, Welsh, Paul, additional, Jhund, Pardeep S., additional, Petrie, Mark C., additional, and McMurray, John J.V., additional

Published
2020
Full Text
View/download PDF

44. The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure

Author

Campbell, Ross T., primary, Jasilek, Adam, additional, Mischak, Harald, additional, Nkuipou‐Kenfack, Esther, additional, Latosinska, Agnieszka, additional, Welsh, Paul I., additional, Jackson, Colette E., additional, Cannon, Jane, additional, McConnachie, Alex, additional, Delles, Christian, additional, and McMurray, John J.V., additional

Published
2020
Full Text
View/download PDF

45. Which patients with heart failure should receive specialist palliative care?

Author

Campbell, Ross T., Petrie, Mark C., Jackson, Colette E., Jhund, Pardeep S., Wright, Ann, Gardner, Roy S., Sonecki, Piotr, Pozzi, Andrea, McSkimming, Paula, McConnachie, Alex, Finlay, Fiona, Davidson, Patricia, Denvir, Martin A., Johnson, Miriam J., Hogg, Karen J., and McMurray, John J.V.

Subjects
Aged, 80 and over, Male, Heart Failure, animal structures, Patient Selection, Palliative Care, fungi, United Kingdom, Hospitalization, Treatment, Cardiovascular System & Hematology, Prevalence, Quality of Life, Humans, Female, Patient Reported Outcome Measures, 1102 Cardiorespiratory Medicine and Haematology, Aged, Follow-Up Studies, Retrospective Studies, Specialization, Research Article
Abstract

Aims:\ud \ud We investigated which patients with heart failure (HF) should receive specialist palliative care (SPC) by first creating a definition of need for SPC in patients hospitalised with HF using patient‐reported outcome measures (PROMs) and then testing this definition using the outcome of days alive and out of hospital (DAOH). We also evaluated which baseline variables predicted need for SPC and whether those with this need received SPC.\ud Methods and results:\ud \ud PROMs assessing quality of life (QoL), symptoms, and mood were administered at baseline and every 4 months. SPC need was defined as persistently severe impairment of any PROM without improvement (or severe impairment immediately preceding death). We then tested whether need for SPC, so defined, was reflected in DAOH, a measure which combines length of stay, days of hospital re‐admission, and days lost due to death. Of 272 patients recruited, 74 (27%) met the definition of SPC needs. These patients lived one third fewer DAOH than those without SPC need (and less than a quarter of QoL‐adjusted DAOH). A Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score of

Published
2018

48. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.

Author

Docherty, Kieran F., Campbell, Ross T., Brooksbank, Katriona J.M., Godeseth, Rosemary L., Forsyth, Paul, McConnachie, Alex, Roditi, Giles, Stanley, Bethany, Welsh, Paul, Jhund, Pardeep S., Petrie, Mark C., and McMurray, John J.V.

Subjects
NEPRILYSIN, HEART failure risk factors, VENTRICULAR remodeling
Abstract

Aims: In patients at high risk of heart failure following myocardial infarction (MI) as a result of residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of adverse left ventricular (LV) remodelling than renin angiotensin aldosterone system inhibition alone, due to increased levels of substrates for neprilysin with vasodilatory, anti‐hypertrophic, anti‐fibrotic, and sympatholytic effects. Methods: We designed a randomized, double‐blinded, active‐comparator trial to examine the effect of sacubitril/valsartan to the current standard of care in reducing adverse LV remodelling in patients with asymptomatic LVSD following MI. Eligible patients were ≥3 months following MI, had an LV ejection fraction ≤40% as measured by echocardiography, were New York Heart Association functional classification I, tolerant of an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker at equivalent dose of ramipril 2.5 mg twice daily or greater, and taking a beta‐blocker unless contraindicated or intolerant. Patients were randomized to sacubitril/valsartan (target dose 97/103 mg twice daily) or valsartan (target dose 160 mg twice daily). The primary endpoint will be change in LV end‐systolic volume indexed for body surface area measured using cardiac magnetic resonance imaging over 52 weeks from randomization. Secondary endpoints include other magnetic resonance imaging‐based metrics of LV remodelling, biomarkers associated with LV remodelling and neurohumoral activation, and change in patient well‐being assessed using a patient global assessment questionnaire. Conclusions: This trial will investigate the effect of neprilysin inhibition on LV remodelling and the neurohumoral actions of sacubitril/valsartan in patients with asymptomatic LVSD following MI. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review

Author

Campbell, Ross T., Willox, Gage P., Jhund, Pardeep S., Hawkins, Nathaniel M., Huang, Flora, Petrie, Mark C., and McMurray, John J. V.

Subjects
humanities
Abstract

Background—Premature treatment discontinuation and loss to follow-up (LTFU) with unknown outcomes leave uncertainty about the true efficacy and safety of a treatment and a lack of confidence in the results of any trial. We reviewed the extent of (and trends over time in) reporting LTFU and treatment discontinuation in large studies in chronic heart failure published since 1990.\ud \ud Methods and Results—Online databases were systematically reviewed to identify randomized controlled clinical trials (RCTs) in chronic heart failure with >400 participants and utilizing all-cause mortality as a component of the primary or secondary end point. Assessments were made of documentation of treatment discontinuation, LTFU, inclusion of and completeness of a Consolidated Standards Of Reporting Trials (CONSORT) diagram, and whether LTFU was differentiated from withdrawal of consent. Sixty-eight trials were identified, with >154 000 participants. Reasons for treatment discontinuation in pharmacotherapy trials were infrequently reported (35%), particularly in a CONSORT diagram (20%). Eighty-three percent of trials reported LTFU, although only 34% of these differentiated LTFU for vital status from withdrawal of consent. Use of a CONSORT diagram increased over time, although reporting of LTFU in the CONSORT diagram remained low overall at 35%.\ud \ud Conclusions—Participant flow through RCTs in chronic heart failure has not been uniformly reported, and the use of a complete CONSORT diagram has been low, although it seems to be improving. All study participants should be accounted for within a CONSORT diagram in any RCT to enable the practicing cardiologist to interpret how the results should influence his/her clinical practice.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results